Allied Market Research published a report, titled, „Autoimmune Disease Testing Market by Product Type (Instruments and Consumables and kits), Disease Type (Rheumatoid Arthritis, Systemic Lupus Erythematous, Scleroderma, Vasculitis, Inflammatory Bowel Disease and Others), Test Type (Antibodies and Immunolgic Test, Inflammatory Markers, Routine Laboratory Tests, Anti-Thyroglobulin Antibody and Others), End User (Hospitals and Clinics, Clinical Laboratories and Others): Global Opportunity Analysis and Industry Forecast, 2024-2033“.
According to the report, the autoimmune disease testing market was valued at $5.3 billion in 2023, and is estimated to reach $12.1 billion by 2033, growing at a CAGR of 8.6% from 2024 to 2033.
Recent Developments in Autoimmune Disease Testing Industry
In July 2022, KSL Beutner Laboratories (Beutner), a global leader in immunologic testing for the diagnosis of bullous, vascular, connective tissue and inherited skin diseases, launched a first-to-market indirect immunofluorescence (IIF) serum blood test in the U.S. that positively identifies laminin 332, an antigen associated with the chronic, debilitating autoimmune disease mucous membrane pemphigoid (MMP).
